PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

PACIFIC Trial Leads to Durvalumab Approval in United States

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

ALK Testing in Europe

Immunotherapy Adverse-Event Treatment Resource Guide

Management of Immunotherapy Toxicity in NSCLC

Exploring the Potential of Immuno-oncology Combination Therapy

Q & A with Yi-Long Wu, MD

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects of BRAF Mutations on Non-small Cell Lung Cancer Outcomes and Therapeutic Selection